Scroll to top

Digital health innovator Gendius signs contract with AstraZeneca to develop diabetes remote management platform for the Gulf region

UK digital health startup Gendius has signed a contract with science-led biopharmaceutical company AstraZeneca to confirm its strategic partnership to develop remote diabetes management to support patients in Gulf Cooperation Council (GCC) countries. The partnership will build upon Gendius’ existing diabetes management platform, Intellin®, which has over 430,000 downloads worldwide.

Gendius CEO, Rory Cameron, comments, “We are thrilled to be working with AstraZeneca on this, it has been great to see a large pharmaceutical company getting behind remote management technology. People across the world now have dramatically reduced in-person access to their healthcare professionals, and so they are increasingly turning to digital tools. This collaboration with AstraZeneca will allow us to bring our remote management technology to thousands of healthcare professionals and patients across the Gulf region, and I look forward to seeing the impact amongst GCC healthcare professionals and patients.”

Through the partnership with AstraZeneca, healthcare professionals across the Gulf region will have access to Gendius’ Intellin® platform to optimise their patients’ diabetes management, in order to reduce the incidence of complications such as cardiovascular disease, kidney disease, amputation, and blindness. The partnership is being implemented within the framework of AstraZeneca’s Emerging Markets Health Innovation Hubs initiative to create integrated science ecosystems through local bio-hubs across the world.

GCC countries have some of the highest prevalence of diabetes in the world, linked to the similarly high levels of obesity[i], and the number of people in GCC countries with type-2 diabetes is projected to increase by 96.3% by 2035[ii]. Studies have shown that diabetes control is poor amongst adults with type-2 diabetes in the GCC.

As a result, the region has a disproportionate number of diabetes complications, for example GCC countries are responsible for 40%-70% of the world’s diabetes-related foot amputationsii. Increased awareness and education about the best ways to manage diabetes and reduce the risk of developing serious complications have been identified as key to addressing the impact of diabetes in the regioni.

Gendius’ Intellin® platform actively monitors patients’ diabetes management and uses their clinical history to highlight their risk for developing diabetes-related complications, such as cardiovascular disease, kidney disease, amputation, and blindness. Its algorithms analyse users’ health and wellbeing data to provide individually tailored, clinically-validated educational content and guidance to help people with diabetes to manage their condition more effectively.

Intellin® is compatible with more than 150 apps and connected health devices, ranging from Fitbit and Garmin devices, to more specialist blood glucose monitors and blood pressure cuffs. Once connected, Intellin® can automatically collect and analyse users’ health data without requiring manual input.

**ENDS**

About Gendius

Gendius is a healthcare technology company based at Alderley Park in Cheshire. It has developed a platform called Intellin®, which uses an algorithm to help diabetes patients to understand their risk of complications and how to manage them.

The Company raised over £500k in just 48 hours through a Crowdcube campaign in 2019, and is a member of the GM Future Healthcare accelerator.


[i] Khalil, Aly Bernard et al. “Diabesity in the Arabian Gulf: Challenges and Opportunities.” Oman medical journal vol. 33,4 (2018): 273-282. doi:10.5001/omj.2018.53

[ii] Al Slamah, Thamer et al. “Self-management of type 2 diabetes in gulf cooperation council countries: A systematic review.” PloS one vol. 12,12 e0189160. 12 Dec. 2017, doi:10.1371/journal.pone.0189160

Related posts